Roche’s decision earlier this year to pluck a new chief executive from the top of its diagnostics pyramid has triggered a domino effect of promotions and replacements, all slated to take effect early next year.
The latest of these appointments concerns the place at the helm of Roche Diagnostics’ North American segment, which is soon to be vacated by Matt Sause as he breaks free of geographical constraints and takes up the reins of Roche’s worldwide diagnostics business. Sause is now set to be replaced in North America by Brad Moore, Roche Diagnostics announced this week.
Moore, who is currently senior VP of the core lab and point of care unit within Roche Diagnostics North America, will step into his new role at the segment’s Indianapolis headquarters on Jan. 1. As president and CEO, he’ll report to Sause and oversee the operations of the Swiss company’s entire North American testing business.
Moore has been at Roche since 2016, when he came aboard as head of its diabetes care division in North America. His domain expanded in 2019 to include the European market, and a year later, he moved to his current position heading up the then-new core lab and point of care business unit at Roche Diagnostics North America.
Before joining Roche, he spent almost two decades at Johnson & Johnson. That span included nearly 14 years within the DePuy Spine device division—including as worldwide VP of marketing and business development—then a couple of years as general manager of the Canadian business of diabetes monitoring subsidiary LifeScan and, finally, a two-year stint as vice president of health system innovation at J&J proper.
“Brad has a proven reputation for delivering outstanding results and is a highly effective leader,” Sause said of the appointment to his former role. “I’m confident his experience will be a tremendous asset for the North America team, our customers and patients.”
Sause, himself a two-decade veteran of the Swiss diagnostics and drugmaker, is moving on up, too, with a Jan. 1 start of his own as CEO of Roche Diagnostics. He’s taking over for Thomas Schinecker, Ph.D., who led the global testmaking division throughout the COVID-19 pandemic and, recently, the ongoing mpox outbreak.
Schinecker’s success under those difficult circumstances helped earn him the top job at Roche: The company announced in July that it had appointed him CEO, effective March 15 of next year.
He’ll in turn be replacing Severin Schwan, who’s been in the Basel HQ’s corner office since 2008. Schwan will transition into the role of chairman of Roche’s board, replacing Chris Franz, who isn’t seeking reelection to the board after nearly a decade as chair.